Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bio-engineered microRNA-7
- Development stage
- Preclinical
- Modality
- Gene Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral, Systemic
01
Overview
Bio-engineered microRNA-7 is a recombinant RNA therapy designed to mimic endogenous miR-7, a tumor-suppressive microRNA. Produced using an Escherichia coli expression system, it is intended for therapeutic use particularly in oncology. Mechanistically, it targets the Akt3/p53 signaling axis—by suppressing Akt3, it decreases phosphorylation/nuclear translocation of MDM2, thereby stabilizing p53 and promoting apoptosis in cancer cells. Preclinical studies have demonstrated that bio-engineered microRNA-7 inhibits cell proliferation, migration, and invasion, and induces apoptosis in non-small cell lung cancer (NSCLC) models, including significant tumor growth repression in vivo.[1][5] Development focuses on its application in NSCLC, with mechanistic implications in other malignancies where miR-7 exerts tumor-suppressive effects.[3]
- Other names
- miR-7miR7miR 7microRNA-7microRNA7microRNA 7engineered miR-7bioengineered miR-7
02
Targets
AKT3 (RAC-gamma serine/threonine-protein kinase)TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on bio-engineered microRNA-7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bio-engineered microRNA-7.